MARKETS
RELIANCETCSHDFCBANKINFYICICIBANKSBINITCLTBHARTIARTLAXISBANKMARUTISUNPHARMA

Kopran Ltd.

KOPRAN · Pharmaceuticals & Drugs
₹261.65
▼ 2.40 (-0.91%)
Market dataas of 22 Oct 2026, 3:58 pm IST
52-week range · NSE11.6% below its high
Low ₹107.00High ₹295.83
144.5% above its low · +56.5% over 52 weeks
Today’s range · NSE₹258.35 – ₹276.00
Low ₹258.35High ₹276.00
Opened at ₹264.00; 6.8% between low and high
P/E against its industry90% above the industry median
KOPRAN49.1
Industry median25.9
Pharmaceuticals & Drugs · median of profitable companies in the industry
Market cap₹1,263 Cr
Current price₹261.65
Volume · NSE6.23 L
52w High / Low · NSE₹296 / ₹107
Stock P/E49.1
Industry P/E25.9
Book value₹109.54
Dividend yield1.15%
ROCE6.6%
ROE4.9%
Debt / Equity0.29
EPS (TTM)₹5.33
Face value₹10

Price

Daily candles · NSE
▲ ₹94.4 (56.45%)over 1Y
100.0150.0200.0250.0300.01.6CrOct 25Jan 26Apr 26Jul 26Oct 26

What the numbers say

  • Low return on equity: 3-year ROE 7.8%.
  • Comfortable leverage: debt-to-equity of 0.29.
  • Sales growth muted at 7.3% over 3 years.
  • Weak cash conversion (CFO/OP 0.67).
  • Trades above its industry P/E (49.1 vs 25.9).

Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.

  • Kopran concludes EU GMP inspection of Khopoli facility

    The inspection was conducted from September 18, 2026 to September 23, 2026

    COMPANY

Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.

Profit & Loss · ₹ croreFY26FY25FY24FY23FY22
Net Sales681630615551478
Other income0415311
Total Income682634629554488
Expenditure619557540499390
Operating Profit6277895598
Interest109965
Depreciation1716131311
Profit before tax3452683682
Tax91317921
Net Profit2639512761
EPS (₹)5.337.9910.575.6513.77
Net margin %3.86.18.34.912.8

Consolidated figures, as filed with the exchanges. Newest year first.

Balance Sheet · ₹ croreFY26FY25FY24FY23FY22
Equity capital4848484848
Reserves481468442391378
Net worth529517490439426
Total sources553546517466453
Net block346208182165151
Capital work in progress25113977036
Investments1413111610
Inventory164169138131150
Debtors263215212163127
Cash & bank726141357
Book value (₹)109.54107.02101.6891.1188.40

Consolidated figures, as filed with the exchanges. Newest year first.

Cash Flow · ₹ croreFY26FY25FY24FY23FY22
From operations67424334-33
From investing-65-56-44-13-84
From financing-21261-20123
Net change in cash-1911125
Free cash flow2-14-021-118
Closing cash119876

Consolidated figures, as filed with the exchanges. Newest year first.

RatiosFY26FY25FY24FY23FY22
ROCE %6.69.813.88.321.4
ROE %4.97.711.06.318.2
PAT margin %3.86.18.34.912.6
EBIT margin %6.69.712.47.617.9
Debt / equity0.290.290.200.170.17
Current ratio1.511.762.082.252.74
Interest cover4.286.568.866.9316.98
Sales growth %8.22.411.515.4-2.9
Dividend per share (₹)3.003.003.003.003.00
Payout %56.337.628.453.123.7

Consolidated figures, as filed with the exchanges. Newest year first.

Frequently asked

Kopran Ltd. (KOPRAN) last traded at ₹261.65 on the NSE, down +0.91% on the session. Prices on this page are indicative and for information only.

Kopran Ltd. has traded between ₹107.00 and ₹295.83 over the last 52 weeks on the NSE.

Kopran Ltd. has a market capitalisation of about ₹1,263 crore.

Kopran Ltd. trades at a P/E of 49.1, against an industry P/E of 25.9.

Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for KOPRAN from the Labdhi app or web platform.

Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.

Who is actually trading it

Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Kopran Ltd..

Loading trading activity…

Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.

Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.

Figures are as reported by the company; consolidated where available. Errors and omissions excepted.

L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in